期刊文献+

常规治疗联合氟哌噻吨美利曲辛片治疗功能性消化不良的临床观察 被引量:10

下载PDF
导出
摘要 目的探讨氟哌噻吨美利曲辛片联合常规药物治疗功能性消化不良的临床观察。方法选取192例功能性消化不良(FD)患者为研究对象,随机分为对照组和观察组。对照组给予常规药物莫沙必利和奥美拉唑口服,观察组在对照组治疗基础上给予氟哌噻吨美利曲辛片治疗,疗程为4周。治疗结束后比较两组患者的治疗总有效率、症状评分、焦虑、抑郁及睡眠质量改善情况。结果治疗4周后,对照组和观察组患者治疗总有效率分别为64.5%和80.2%,两组比较差异有统计学意义(P<0.05);两组患者的症状评分、焦虑、抑郁情况及睡眠质量较治疗前均显著改善,差异具有统计学意义(P<0.05)。结论氟哌噻吨美利曲辛联合莫沙必利和奥美拉唑治疗功能性消化不良患者的疗效优于应用莫沙必利和奥美拉唑的常规治疗,有助于改善患者情绪状态和睡眠质量,值得在临床推广。
作者 温伟航
出处 《内科》 2015年第3期322-323,317,共3页 Internal Medicine
  • 相关文献

参考文献11

  • 1Lacy BE, TaUey N J, Locke GR, et al. Review article : current treatment options and management of functional dyspepsia [ J ]. Alimentary pharmacology & therapeutics, 2012, 36(1) :3 -15.
  • 2Drossman DA. The functional gastrointestinal disorders and the Rome II process [ J ]. Gut, 1999,45 ( suppl 2 ) : II1 - II5.
  • 3Hojo M, Miwa H, Yokoyama T, et al. Treatment of functional dyspepsia with antianxiety or antidepressive agents : system- atic review [ J 1- Journal of gastroenterology, 2005,40 ( 11 ) : 1036 - 1042.
  • 4Tack J, Janssen P. Emerging drugs for functional dyspepsia [J]. Expert opinion on emerging drugs, 2011, 16 (2): 283 - 292.
  • 5Zigmond AS, Snaith RP. The hospital anxiety and depression scale [ J ]. Aeta Psychiatr Stand, 1983,67 ( 6 ) : 361 - 370.
  • 6Buysse DJ, Reynolds CF, Monk TH, et al. Quantification of subjective sleep quality in healthy elderly men and women using the Pittsburgh Sleep Quality Index (PSQI) [ j ]. Sleep:Journal of Sleep Research & Sleep Medicine, 1991,14(4) :331 -338.
  • 7Hsu YC, Liou JM, Yang TH, et aL Proton pump inhibitor versus prokinetie therapy in patients with functional dyspep- sia:is therapeutic response predicted by Rome III subgroups E J 1- J Gastroentero1,2011,46 ( 2 ) : 183 - 190.
  • 8郝丽萍,赖洁莹.抗焦虑抑郁药物联合治疗餐后不适综合征和上腹痛综合征的临床观察[J].临床消化病杂志,2010,22(5):282-284. 被引量:8
  • 9高峰玉.盐酸伊托必利联合黛力新治疗功能性消化不良136例分析[J].实用医学杂志,2011,27(2):293-295. 被引量:32
  • 10季洁如,高玮,许平,王天蓉,陈胜良.莫沙必利治疗餐后不适综合征和上腹痛综合征随机、双盲、安慰剂对照研究[J].胃肠病学,2008,13(11):655-658. 被引量:15

二级参考文献45

  • 1袁耀宗,邹多武,汤玉茗,许国铭.胃食管反流病的蒙特利尔(Montreal)定义和分类——基于循证医学的全球共识[J].中华消化杂志,2006,26(10):686-689. 被引量:109
  • 2Karamanolis G, Caenepeel P, Arts J, et al. Association of the predominant symptom with clinical characteristics and pathophysiological mechanisms in functional dyspepsia. Gastroenterology, 2006, 130 (2): 296-303.
  • 3Design of Treatment Trials Committee; Irvine E J, Whitehead WE, Chey WD, et al. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology, 2006, 130 (5): 1538-1551.
  • 4Hiyama T, Yoshihara M, Matsuo K, et al. Meta-analysis of the effects of prokinetic agents in patients with functional dyspepsia. J Gastroenterol Hepatol, 2007, 22 (3): 304-310.
  • 5Tack J, Talley N J, Camilleri M, et al. Functional gastroduodenaldisorders. Gastroenterology, 2006, 130 (5): 1466-1479.
  • 6Oshima T, Miwa H. Treatment of functional dyspepsia: where to go and what to do. J Gastroenterol, 2006, 41 (7): 718-719.
  • 7Talley N J, Locke GR, Lahr BD, et al. Predictors of the placebo response in functional dyspepsia. Aliment Pharmacol Ther, 2006, 23 (7): 923-936.
  • 8Suzuki H, Nishizawa T, Hibi T. Therapeutic strategies for functional dyspepsia and the introduction of the Rome Ⅲ classification. J Gastroenterol, 2006, 41 (6): 513-523.
  • 9Mizuta Y, Shikuwa S, Isomoto H, et al. Recent insights into digestive motility in functional dyspepsia. J Gastroenterol, 2006, 41 (11): 1025-1040.
  • 10Talley N J, Locke GR 3rd, Lahr BD, et al. Functional dyspepsia, delayed gastric emptying, and impaired quality of life. Gut, 2006, 55 (7): 933-939.

共引文献63

同被引文献54

引证文献10

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部